Open AccessEfficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
Author(s) -
Charles A. Gordon,
Gregory A. Fabiano,
Kevin F. Hulme,
Sandro M. Sodano,
Michael S. Adragna,
Rachel Lim,
Samantha Stanford,
Leah Janikowski,
Bradley Bufalo,
Zulema Morejón Rodríguez,
Denise Swiatek
Publication year - 2021
Publication title -
experimental and clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.066
H-Index - 92
eISSN - 1936-2293
pISSN - 1064-1297
DOI - 10.1037/pha0000365
Subject(s) - psycinfo , placebo , attention deficit hyperactivity disorder , psychology , clinical psychology , psychological intervention , stimulant , psychiatry , medline , medicine , alternative medicine , pathology , political science , law
There has been a lack of research on the third area of impairment noted in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition -"occupational functioning." It is important to understand the impact of common treatments for attention-deficit/hyperactivity disorder (ADHD) in occupational settings. Twenty individuals with ADHD between ages 16 and 25 participated in a double-blind, placebo controlled evaluation of 40 mg lisdexamfetamine dimesylate in a setting designed to approximate a restaurant workplace with associated, simulated food delivery. Outcome measures included ratings of performance, as well as behavioral productivity. Results indicated that participants completed more workplace tasks when on medication, relative to placebo. Ratings of job application quality, job interview performance, and delivery outcomes were not significantly different on medication versus placebo. These results suggest positive effects of medication in a workplace environment, but also a need for study of additional interventions to support workplace-related behavior and functioning. (PsycInfo Database Record (c) 2021 APA, all rights reserved).